10-K: 89bio Reports Full Year 2024 Results, Highlights Progress of Pegozafermin in MASH and SHTG

89bio, a clinical-stage biopharmaceutical company, provides an update on its financial results for the year ended December 31, 2024, and highlights the advancement of its lead product candidate, pegozafermin, in clinical trials for MASH and SHTG.

Summary

• 89bio is a clinical-stage biopharmaceutical company focused on developing therapies for liver and cardio-metabolic diseases.
• Their lead product candidate, pegozafermin, is being developed for metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
• In March 2024, the ENLIGHTEN-Fibrosis Phase 3 trial was initiated for MASH patients with fibrosis stage F2-F3.
• In May 2024, the ENLIGHTEN-Cirrhosis Phase 3 trial was initiated for MASH patients with compensated cirrhosis (F4).
• Topline data from the histology cohorts of the ENLIGHTEN-Fibrosis trial is expected in the first half of 2027, and from the ENLIGHTEN-Cirrhosis trial in 2028.
• Enrollment in the ENTRUST Phase 3 trial for SHTG patients was completed in December 2024 with 369 patients.
• Topline data from the ENTRUST trial is expected in the first quarter of 2026.
• The company reported net losses of $367.1 million for 2024, $142.2 million for 2023 and $102.0 million for 2022.
• As of December 31, 2024, the company had cash, cash equivalents, and marketable securities of $440.0 million.
• The company believes its existing cash, cash equivalents and marketable securities, supplemented by $269.9 million in net proceeds from its February 2025 equity offering, will be sufficient to fund its projected operating requirements for at least one year.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. Positive clinical trial progress is balanced by significant financial losses. The company's ability to fund operations for at least a year is reassuring, but the high cash burn rate is a concern.

Positives

• Phase 3 trials are underway for pegozafermin in both MASH and SHTG.
• The company has completed enrollment in the ENTRUST trial for SHTG.
• The company believes its existing cash, cash equivalents and marketable securities, supplemented by $269.9 million in net proceeds from its February 2025 equity offering, will be sufficient to fund its projected operating requirements for at least one year.

Negatives

• The company reported a significant net loss of $367.1 million for 2024.
• The company has an accumulated deficit of $824.5 million as of December 31, 2024.

Risks

• The company is dependent on the success of pegozafermin.
• Clinical drug development is a lengthy and expensive process with uncertain timelines and outcomes.
• The company will require substantial additional capital to finance its operations.
• The company faces substantial competition in the biopharmaceutical industry.
• The company relies on third-party manufacturers and vendors to produce pegozafermin.
• Pegozafermin may cause undesirable side effects.
• The requirements for approval of pegozafermin by the FDA and comparable foreign regulatory authorities may be difficult to predict and may change over time.
• Lack of efficacy, adverse events or undesirable side effects may emerge in clinical trials conducted by third parties developing FGF product candidates, which could adversely affect our stock price, our ability to attract additional capital and our development program.
• Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

Future Outlook

The company expects its existing cash, cash equivalents and marketable securities, supplemented by $269.9 million in net proceeds from its February 2025 equity offering, will be sufficient to fund its planned operating expenses and capital expenditure requirements for a period of at least one year following the filing of this Form 10-K.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on liver and cardio-metabolic diseases, specifically MASH and SHTG. The document mentions competitors developing therapies for the same indications, highlighting the need for 89bio to demonstrate the efficacy and safety of pegozafermin.

Comparison to Industry Standards

• The document mentions Rezdiffra, developed by Madrigal Pharmaceuticals, Inc., which received regulatory approval for the treatment of non-cirrhotic MASH.
• The document mentions resmetirom, an approved therapy for F2-F3 MASH, which is a thyroid hormone receptor beta agonist from Madrigal Pharmaceuticals, Inc.
• The document mentions semaglutide, a GLP-1 receptor agonist from Novo Nordisk A/S.
• The document mentions efruxifermin, an FGF21 analog from Akero Therapeutics, Inc.
• The document mentions lanifibranor, a pan-peroxisome proliferator-activated receptor alpha/delta/gamma agonist from Inventiva.
• The document mentions survodutide, a glucagon/GLP-1 receptor dual agonist from Boehringer Ingelheim.
• The document mentions denifanstat, a selective Fatty Acid Synthase inhibitor from Sagimet Biosciences Inc.
• The document mentions zalfermin/NNC0194-0499, an FGF21 analog from Novo Nordisk.
• The document mentions efimosfermin alfa/BOS-580, an FGF21 analog from Boston Pharmaceuticals.
• The document mentions Vascepa, a pure eicosapentaenoic acid (EPA) from Amarin Corp, and Lovaza, an EPA and docosahexaenoic acid from GlaxoSmithKline, as well as generic products.
• The document mentions olezarsen/AKCEA-APOCIII-LRx, an APOC3 inhibitor from Ionis; and plozasiran, an ApoC-III inhibitor from Arrowhead Pharmaceuticals, Inc.

Legal Proceedings

• In December 2023, the Israeli Tax Authorities issued a tax assessment claiming our 2019 reorganization and intercompany transaction to license the intellectual property rights from our subsidiary in Israel should be treated as a sale of intellectual property rights.
• As of December 31, 2024, discussions with the Israel Tax Authorities are ongoing.

Stakeholder Impact

• Shareholders: Dilution from equity offerings, potential for long-term value creation through successful drug development.
• Employees: Job security and potential for career growth within the company.
• Patients: Potential access to new therapies for MASH and SHTG.
• Suppliers: Continued business relationships and potential for increased demand.
• Creditors: Repayment of debt obligations.

Next Steps

• Continue Phase 3 clinical trials for pegozafermin in MASH (ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis).
• Report topline data from the ENTRUST Phase 3 trial for SHTG in Q1 2026.
• Advance pegozafermin through clinical development and seek regulatory approvals.
• Scale-up and optimize the manufacturing of pegozafermin.
• Establish a commercial infrastructure in key geographies.

Key Dates